search
Back to results

Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients (ITCA-ThyCa)

Primary Purpose

Thyroid Cancer

Status
Withdrawn
Phase
Phase 1
Locations
Canada
Study Type
Interventional
Intervention
Interdisciplinary Team-Based Approach
Usual Care Control
Sponsored by
Jewish General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Thyroid Cancer focused on measuring Thyroid cancer, New diagnosis, Dedicated Nurse, Interdisciplinary team, Randomized Controlled Trial, Intervention, Supportive care

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Newly diagnosed with a first occurrence of thyroid cancer <2-4 weeks of diagnosis (i.e., histologically confirmed thyroid cancer (papillary, follicular, or medullary type; TNM classification system);
  • Willing to participate in the EG meetings;
  • >18 years;
  • Alert and capable of giving free and informed consent;
  • Able to speak and read English or French.

Exclusion Criteria:

  • Anaplastic thyroid cancer;
  • Karnofsky Performance Status (KPS) score <60 (rated by the Research Coordinator (RC) or referring physician) or expected survival <6 months according to clinical judgment.

Sites / Locations

  • Jewish General Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Interdisciplinary Team-Based Approach

Usual Care Control Group

Arm Description

The delivered intervention will be to provide patients with an interdisciplinary team-based approach defined as care provided by a variety of professionals, each having their own domain of expertise, defined roles and responsibilities, who work together and meet to discuss patient needs and develop comprehensive treatment plans. Team composition will include physicians, a dedicated nurse, and allied professionals (e.g., dieticians, social workers, psychologists). The dedicated nurse will have a central integrative role in this interdisciplinary team and will provide patients with information about their illness and treatment, symptom management, emotional support, and reference to other resources when needed

Patients in the control group will be provided with usual care, comprised of meetings with surgeons and endocrinologists. All patients in this study will be provided with an information website containing information on their cancer, treatments, and treatment side-effects.

Outcomes

Primary Outcome Measures

Overall quality of life
Measure: Functional Assessment of Chronic Illness Therapy-General (FACT-G)

Secondary Outcome Measures

Level of physical health
Measure: SF-36 Physical Health subscale
Level of mental health
Measure: SF-36 Mental Health subscale
Level of fatigue
Measure: Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)
Level of anxiety and depression (combined)
Measure: Hospital Anxiety and Depression Scale (HADS)
Level of negative illness perception
Illness Perception Questionnaire - Revised (IPQ-R)
Level of satisfaction with care
16 questions of the NRC Picker satisfaction survey measuring patient satisfaction with care
Healthcare service use
Types of professionals consulted, frequency of visits, and time elapsed between referral and first consultation

Full Information

First Posted
November 19, 2013
Last Updated
February 22, 2016
Sponsor
Jewish General Hospital
Collaborators
Genzyme, a Sanofi Company
search

1. Study Identification

Unique Protocol Identification Number
NCT01994200
Brief Title
Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients
Acronym
ITCA-ThyCa
Official Title
Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) For Newly Diagnosed Thyroid Cancer Patients: Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2016
Overall Recruitment Status
Withdrawn
Study Start Date
September 2014 (undefined)
Primary Completion Date
June 2016 (Anticipated)
Study Completion Date
June 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Jewish General Hospital
Collaborators
Genzyme, a Sanofi Company

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
While thyroid cancer is generally associated with a favourable prognosis, there is a discrepancy with how important if not traumatic its impact can be on patients. Quality of life (QoL) decreases in the year following a thyroid cancer diagnosis, constituting an optimal period for a preventive intervention. The goal of this study is to evaluate the impact of offering an interdisciplinary team-based care approach for newly diagnosed thyroid cancer patients, including a dedicated nurse who will provide important psychoeducational elements identified in previous focus group studies of thyroid cancer patients, i.e., information on: the physical illness; the emotional impact of being newly diagnosed with thyroid cancer; surgery and its' short- and long-term consequences; radioactive iodine treatments and its associated safety precautions, nutrition and dietary considerations; and how the cancer diagnosis can be an opportunity to make important lifestyle changes and establish new life-priorities.
Detailed Description
The investigators will conduct a 2-arm Randomized Controlled Trial comparing an Interdisciplinary Team-Based Care Approach to usual care. The primary research question will be: Does adding the Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) to usual care (EG) increase levels of overall QoL among newly diagnosed thyroid cancer patients, compared with those receiving usual care (UC), at 9 months post-randomization (i.e., after all of the dedicated-nurse meetings are administered) as judged by scores on the Functional Assessment of Chronic Illness Therapy-General (FACT-G)? Primary hypothesis: The EG will report higher scores of overall QoL on the FACT-G than the UC at 9 months post-randomization. Secondary research questions: The investigators plan to evaluate ITCA-ThyCa effects on secondary outcomes such as level of: physical health (SF-36 Physical Health subscale), mental health (SF-36 Mental Health subscale), fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue; FACIT-F), anxiety and depression (Hospital Anxiety and Depression Scale; HADS), and negative illness perception (Illness Perception Questionnaire - Revised (IPQ-R). The investigators also plan to explore ITCA-ThyCa effects on satisfaction with care (16 questions of the NRC Picker satisfaction survey measuring patient satisfaction with care) and healthcare service use (types of professionals consulted, frequency of visits, and time elapsed between referral and first consultation). Hypotheses: The EG will report a higher level of physical and mental health on the SF-Physical and Mental Health subscales, respectively; and a lower level of fatigue on the FACIT-F, anxiety and depression on the HADS, and negative illness perception on the IPQ-R; compared with the UC at 9 months post-randomization. All of the abovementioned changes will be present throughout the treatment, namely at 7-10 days and 5 months post-randomization (i.e., immediately after each of the meetings planned with the dedicated nurse). All of the abovementioned changes will persist at 12 months post-randomization (i.e., corresponding to 6 months after all anti-cancer treatments are completed and 3 months after all dedicated-nurse meetings have been administered). Feasibility and acceptability (9 first months of the trial): The investigators plan on testing the feasibility and acceptability of the 2-arm RCT of ITCA-ThyCa during the first 9 months of the trial (once the investigators start recruiting, after the first 3-6 months dedicated to hiring our personnel and developing the manual of our approach). During this phase, the investigators will aim to address the following research questions: Can the investigators recruit a sufficient number of patients (i.e., a minimum of 60 patients over 6 months or 10/month) and retain a sufficient proportion of thyroid cancer patients (i.e., at least 80% at 7-10 days, 5 months or 9 months post-randomization) in both trial arms? Is ITCA-ThyCa acceptable to at least 80% of EG thyroid cancer patients? Secondary pilot study questions Which evaluation time should be primary post-randomization, based on an acceptable retention rate of 80%? What variance estimates can be used to inform calculation of sample size for the full study? If the design remains the same following this pilot, the investigators aim to roll in the pilot data in the full trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Thyroid Cancer
Keywords
Thyroid cancer, New diagnosis, Dedicated Nurse, Interdisciplinary team, Randomized Controlled Trial, Intervention, Supportive care

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Interdisciplinary Team-Based Approach
Arm Type
Experimental
Arm Description
The delivered intervention will be to provide patients with an interdisciplinary team-based approach defined as care provided by a variety of professionals, each having their own domain of expertise, defined roles and responsibilities, who work together and meet to discuss patient needs and develop comprehensive treatment plans. Team composition will include physicians, a dedicated nurse, and allied professionals (e.g., dieticians, social workers, psychologists). The dedicated nurse will have a central integrative role in this interdisciplinary team and will provide patients with information about their illness and treatment, symptom management, emotional support, and reference to other resources when needed
Arm Title
Usual Care Control Group
Arm Type
Other
Arm Description
Patients in the control group will be provided with usual care, comprised of meetings with surgeons and endocrinologists. All patients in this study will be provided with an information website containing information on their cancer, treatments, and treatment side-effects.
Intervention Type
Other
Intervention Name(s)
Interdisciplinary Team-Based Approach
Other Intervention Name(s)
Interdisciplinary Team-Based Approach (ITCA-ThyCa)
Intervention Description
Three meetings will be scheduled with the oncology dedicated-nurse. First meeting: information about the physical illness; the emotional impact of being newly diagnosed with thyroid cancer; as well as surgery and its' short- and long-term consequences. Second meeting: information on radioactive iodine treatments and its associated safety precautions, nutrition and dietary considerations. Third meeting: how the cancer diagnosis can be an opportunity to make important lifestyle changes and establish new life-priorities. The dedicated nurse, in collaboration with the Department of Nursing and ENT, will develop and implement an interdisciplinary team-based approached developed for this study according to guidelines of the Programme québécois de lutte contre le cancer (PQLC).
Intervention Type
Other
Intervention Name(s)
Usual Care Control
Intervention Description
Patients in the control group will be provided with usual care, comprised of meetings with surgeons and endocrinologists. All patients in this study will be provided with an information website containing information on their cancer, treatments, and treatment side-effects.
Primary Outcome Measure Information:
Title
Overall quality of life
Description
Measure: Functional Assessment of Chronic Illness Therapy-General (FACT-G)
Time Frame
9 months post-randomization
Secondary Outcome Measure Information:
Title
Level of physical health
Description
Measure: SF-36 Physical Health subscale
Time Frame
9 months post-randomization
Title
Level of mental health
Description
Measure: SF-36 Mental Health subscale
Time Frame
9 month post-randomization
Title
Level of fatigue
Description
Measure: Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)
Time Frame
9 months post-randomization
Title
Level of anxiety and depression (combined)
Description
Measure: Hospital Anxiety and Depression Scale (HADS)
Time Frame
9 month post-randomization
Title
Level of negative illness perception
Description
Illness Perception Questionnaire - Revised (IPQ-R)
Time Frame
9 month post-randomization
Title
Level of satisfaction with care
Description
16 questions of the NRC Picker satisfaction survey measuring patient satisfaction with care
Time Frame
9 month post-randomization
Title
Healthcare service use
Description
Types of professionals consulted, frequency of visits, and time elapsed between referral and first consultation
Time Frame
Over 9 months post-randomization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Newly diagnosed with a first occurrence of thyroid cancer <2-4 weeks of diagnosis (i.e., histologically confirmed thyroid cancer (papillary, follicular, or medullary type; TNM classification system); Willing to participate in the EG meetings; >18 years; Alert and capable of giving free and informed consent; Able to speak and read English or French. Exclusion Criteria: Anaplastic thyroid cancer; Karnofsky Performance Status (KPS) score <60 (rated by the Research Coordinator (RC) or referring physician) or expected survival <6 months according to clinical judgment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Melissa Henry, PhD
Organizational Affiliation
Jewish General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Jewish General Hospital
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3T 1E8
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients

We'll reach out to this number within 24 hrs